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Background: An important goal of stem cell research in orthopaedics is to develop clinically relevant
techniques that could be applied to heal cartilage or joint pathology. Stem cell treatment in orthopaedics
for joint pathology is promising since these cells have the ability to modulate different processes in the
various tissues of the joint simultaneously. The non life-threatening nature of musculoskeletal system
disorders makes safety of stem cell therapy a necessary prerequisite.
Objective: To systematically review the literature and provide an overview of reported adverse events
(AEs) of intra-articular treatment with culture-expanded stem cells in humans.
Design: A systematic literature search was performed in Pubmed, EMBASE, Web of Science and CINAHL in
February 2013. AEs were reported into three categories: local/systemic, serious adverse event or AE (SAE/
AE), related/unrelated.
Results: 3039 Potentially eligible articles were identiﬁed of which eventually eight fulﬁlled our inclusion
criteria. In total, 844 procedures with a mean follow-up of 21 months were analysed. Autologous bone
marrow-derived mesenchymal stem cells (BM-MSCs) were used for cartilage repair and osteoarthritis
treatment in all included studies. Four SAEs were reported by the authors. One infection following bone
marrow aspiration (BMA) was reported as probably related and resolved with antibiotics. One pulmonary
embolism occurred 2 weeks after BMA and was reported as possibly related. Two tumours, both not at
the site of injection, were reported as unrelated. Twenty-two other cases of possible procedure-related
and seven of possible stem cell-product related adverse events (AEs) were documented. The main AEs
related to the procedure were increased pain/swelling and dehydration after BMA. Increased pain and
swelling was the only AE reported as related to the stem cell-product.
Conclusions: Based on current literature review we conclude that application of cultured stem cells in
joints appears to be safe. We believe that with continuous caution for potential side effects, it is
reasonable to continue with the development of articular stem cell therapies.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Stem cell therapies are rapidly emerging as a potential strategy
for tissue repair and regeneration in many ﬁelds of medicine1. The
use of autologous or allogenic stem cells is very promising for
biological modulation and repair of various disease processes of the
musculoskeletal system. In the ﬁeld of orthopaedics, cartilage
repair has played a pioneering role in the translational application
of cell therapy. Autologous chondrocyte implantation (ACI) andto: P.K. Bos, Erasmus MC,
rthopaedics, s-Gravendijkwal
The Netherlands.
s Research Society International. Pderivative techniques such as matrix-induced chondrocyte im-
plantation (MACI) have been employed and evaluated in the last
two decades. Generally good to excellent results have been re-
ported for these cell transplantation techniques, without signiﬁcant
safety problems for this intra-articular use of differentiated cells2,3.
The Use of differentiated cells leads to several limitations in num-
ber of cells available, choice of cell and donor-site morbidity4e6.
Stem cells, on the contrary, are multipotent, can be harvested from
many different cell sources and have a high proliferation potential7.
Stem cells have already been used in orthopaedic applications,
although experimentally, in the treatment of avascular bone ne-
crosis, osteochondral defects, pseudoarthrosis and traumatic
cartilage defects8e11. Recently, Pastides et al. provided an overview
of the effectivity of the clinical application of stem cells in cartilage
defects12.ublished by Elsevier Ltd. All rights reserved.
Table I
Search strategy in Medline
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of stem cell therapies. Unlike for life-threatening diseases where
stem cell therapy is used for heart failure following myocardial
infarction13, severe graft vs host disease (GVHD)14, Crohn’s dis-
ease15 or leukaemia, diseases in the orthopaedic ﬁeld eligible for
stem cell therapy are generally not life-threatening. For thisFig. 1. Study sreason, intensive monitoring of the safety of intra-articular use of
culture-expanded stem cells in musculoskeletal diseases is even
more important. This systematic literature review provides an
overview of reported AEs based on all published studies with
human cases of intra-articular treatment with culture-expanded
stem cells.
Methods
Search strategy
A comprehensive search of the literature was carried out in
February 2013. Electronic databases e PubMed, EMBASE, Web of
Science and CINAHL e were used to identify relevant studies since
their inception up to February 2013. An overview of the complete
search strategy is shown in Table I.
Inclusion and exclusion criteria
The articles retrieved from the search were included in this
systematic review according to the following inclusion and exclu-
sion criteria:
(1) Subjects were treated with culture-expanded stem cells in
joints. To obtain an extensive perspective on safety, studies
with the use of all sorts of stem cells were included, as long as
the cells were culture-expanded and applied in joints. No re-
striction was made on joint disease.
(2) Human subjects.election.
Table II
Methodological quality criteria
Item Judgement
1. Did the authors state a prospective
evaluation of AEs? (¼active mode of
AEs collection)
Yes/No/Unable to
determine
2. Were adequate methods for monitoring
AEs reported?
A) MRI, arthroscopy Yes/No/Unable to
determine
B) Prospective checklist and/or patient
questionnaire or patient diary
Yes/No/Unable to
determine
3.
A) Was the number of participants that
withdraw or were lost to follow-up speciﬁed?
Yes/No/Unable to
determine
B) Were patients excluded from the AEs
analysis because of an AE?
Yes/No/Unable to
determine
4.
A) Were all categories of AEs reported on (all AEs)? Yes/No/Unable to
determine
B) Did the study specify whether AEs related
to harvesting, application procedure or cell product?
Yes/No/Unable to
determine
5.
A) Were SAE precisely deﬁned? Yes/No/Unable to
determine
B) For SAE were all categories of AEs reported on? Yes/No/Unable to
determine
6. Did the study specify who collected the AEs? Yes/No/Unable to
determine
7. Did the study specify the timing and frequency
of collection of the AEs?
Yes/No/Unable to
determine
8. Was the follow-up of AEs evaluation at least
1 year after the last administration of stem cells?
Yes/No/Unable to
determine
Item 4 was scored yes when the following 2/3 categories were reported: local/
systemic, serious/nonserious, related/unrelated. Our deﬁnitions: local AE, AE limited
to the joint; systemic AE, AE unrelated to the joint; SAEs includes death, neoplasms,
infections, pulmonary embolisms, anaphylactic shock and leukaemia.
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(4) Study published in English, Dutch, German, Italian, French or
Spanish.
(5) Study had to report information about AEs.
In vitro studies and animal studies were considered ineligible for
inclusion. Comments, editorials, reviews, letters, guidelines and
protocols were also excluded.
In case of potential duplicate studies or studies with overlap (i.e.,
dynamic cohorts) we contacted the senior authors. In those cases
the study with the longest follow-up time and/or more detailed
presentation of relevant outcomes was included in the review.
Of the included studies, only intra-articular procedures with
culture-expanded stem cells were considered eligible for analysis,
procedures invertebraldiscs andother treatment siteswereexcluded.
Study selection
Two reviewers (PB and CP) independently examined article ti-
tles and abstracts for eligibility. Subsequently, full-text reports of
potential studies were screened to determine ﬁnal eligibility for
inclusion in this review. Disagreements concerning the inclusion of
the studies were solved by consensus. A third reviewer (MR) was
consulted when disagreement persisted. Disagreements were
solved in a single consensus meeting without the help of the third
reviewer. In addition, the reference lists of the selected papers were
screened with the intention to add eligible studies that were not
found with the search. The selection of articles is shown sche-
matically in Fig. 1.
Data extraction and presentation
One author (CP) extracted the data of the ﬁnally included
studies. Information was collected on study design, study popula-
tion, origin stem cells, procedure, outcome measures, duration of
follow-up and results. All reported AEs are listed in the results. The
AEs are subdivided in three tables: complications reported as
possibly related to the procedure, stem cell product complications
reported as possibly related and AEs reported as unrelated to the
procedure or stem cell product. Reported AEs are once more sub-
divided in local or systemic and serious adverse events (SAE) or
other AE. Since no deﬁnition of SAE for this application was avail-
able we deﬁned SAE as death, neoplasms, infections, pulmonary
embolisms, anaphylactic shock and haematological neoplasms.
Quality assessment
Two authors (CP and ML) independently assessed the method-
ological quality of AEs collection of each included study, using
questions from the McHarm quality assessment scale for AEs16 (the
eight quality criteria are listed in Table II). Each itemwas scored as a
‘yes, ‘no’ or ‘unable to determine’. Disagreements were resolved by
consensus. Consultation of a third reviewer (GO) when disagree-
ment persisted, appeared unnecessary.
Results
Study inclusion and characteristics
A total of 4035 records were found after the electronic search
(Fig. 1). After the removal of duplicates, 3039 potentially eligible
articles were identiﬁed. Finally, eight articles fulﬁlled our inclusion
criteria and are included in this systematic review9,17e23 (Table III).
Wakitani and Centeno were contacted for potential duplicate or
near duplicate studies. Wakitani reported that all subjects reportedin his six papers were included in Wakitani et al., 201122,24e28.
Centeno reported that his last safety article9 included all subjects
reported in his ﬁve papers9,29e32.
The prospective cohort study of Centeno et al., 2010 has been
updated in 20119,32. The study of 2011 reports changes and AEs
since the last reporting in 2010, which made it difﬁcult to obtain a
complete overview of the AEs in numbers and details. Therefore
Centeno was requested for a complete overview of their reported
AEs, which made enumeration and classiﬁcation possible. We
report the AEs based on the acquired list.
From a total of 904 procedures in 470 individuals, 844 were
intra-articular procedures (789 injections and 55 cell constructs or
sheets) and were analysed with a mean follow-up of 21 months. All
included studies used autologous bone marrow-derived mesen-
chymal stem cells (BM-MSCs). The MSCs were implanted in the
knee joint (503 procedures), hip joint (219), foot/ankle joint (55),
shoulder joint (48), hand/wrist joint (15) and elbow joint (4). Ac-
cording to our inclusion criteria, we have excluded 34 vertebral disc
procedures and 26 procedures in various other treatment sites re-
ported in the study of Centeno et al.9.
Quality assessment
According to the quality assessment (Table IV), the study of
Centeno et al., 2011 described an adequate method regarding the
AEs collection9. All other included studies reported information on
AEs, but did not use a standardised method for AE monitoring.
SAEs
Four SAEs have been reported: one infection, one pulmonary
embolism and two tumours9. The infectionwas at the bonemarrow
Table III
Characteristics of the included studies
First author,
year of
publication
Design Study
population
Number of
procedures
(joints)
[individuals]*
Origin stem cells Serum used
for expansion
in culture
Number of
passages
in culture
Number of
intra-articular
injected cells
(mean)
Adjuvant of injected/implanted
MSCs
Different
joint types
(%)
Mean age
at surgery
in years 
SD (range)
Male
(%)
Mean
follow-up
period 
SD (range)
Centeno et al.,
20119
Prospective
cohort study
Chronic or
degenerative
joint disease
709, (NA),
[>279]y
Autologous iliac
crest BM-MSCs
PL 2e7 NA MSCs in autologous PL10e20%
diluted in PBS or conditioned
serum of PRP
Knee (52.8%)
Hip (30.7%)
Foot/ankle
(7.6%) Shoulder
(6.8%) Hand/
wrist (2.1%)
53 
13.85
63.1 435 days 
261 days
Davatchi et al.,
201117
Pilot study OA 4, (4), [4] Autologous iliac
crest BM-MSCs
FBS 1 8e9  106 Normal saline supplemented wi
2% human serum albumin
Knee (100%) 57.6
(54e65)
50 1 year
Emadedin et al.,
201218
Clinical trial OA 6, (6), [6] Autologous iliac
crest BM-MSCs
HBS 2 20e24  106 Physiological serum Knee (100%) 54.6 0 1 year
Haleem et al.,
201019
Pilot study OD, OCD 5, (5), [5] Autologous iliac
crest BM-MSCs
FBS 1 2  106/cm2 MSC mixed with allogenous
PR-FG and left to gelate
Knee (100%) 25.7
(21e37)
80 14.2 months
Kasemkijwattana
et al., 201120
Case
serie
CD 2, (2), [2] Autologous iliac crest
BM-MSCs
FBS 2 NA MSCs seeded in collagen scaffol
ﬁxed, with FG
Knee (100%) 24.5
(24e25)
100 30.5 months
(30e31)
Lee et al., 201223 Prospective
cohort study
CD 70, (70),
[70]
Autologous iliac
crest BM-MSCs
FBS 1 10  l06 In autologous serum followed
by 2 ml HA injection
Knee (100%) 44 51.4 24.5 months
Teo et al., 201221 Case serie OD 3, (3), [3] Autologous iliac
crest BM-MSCs
FBS NA 10-15  106 Cell sheets in autologous serum
ﬁxed with FG
Knee (100%) NA NA NA
Wakitani et al.,
201122
Prospective
cohort study
OA, CD 45, (45),
[41]z
Autologous iliac
crest BM-MSCs
FCS
(until 2003)
AS
(since 2003)
2 NA Until 2003: embedded in 0.25%
acid-soluble type I collagen from
porcine tendon and gelated or
placed on a collagen sheet and
gelated in DMEM þ 15%
autologous serum. Since 2003:
embedded in 1% acid-soluble typ I
collagen from bovine skin, gelat
on porcine tendon collagen shee
in a MEM þ 15% autologous seru
Knee (86.7%)
Ankle (2.2%)
Hip (2.2%)
Elbow (8.9%)
50 NA 75 months
(5e137)
OA: osteoarthritis, OD: Osteochondritis dissecans, OCD: osteochondral defect, CD: chondral defect, PL: platelet lysate, FBS: fetal bovine serum, HBS: hyclone bovine se um, FCS: fetal calf serum, AS: autologous serum, NA: not
available, PR-FG: platelet-rich ﬁbrin glue, FG: ﬁbrin glue, HA: hyaluronic acid.
* Joints: total number of joints injected, procedures: total joint procedures.
y Including three patients of three Case reports of Centeno et al., 2008 and 222 procedures of Centeno et al., 2010. The exact number of patients is not determinable a r exclusion of disc procedures and other site treatments.
z Including 12 patients of Wakitani et al., 2002, two patients of Wakitani et al., 2004, three patients of Wakitani et al., 2006, one patient of Kuroda et al., 2007 and ree patients of Wakitani et al., 2007.
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Table IV
Quality assessment
Item Centeno
et al., 20119
Davatchi
et al., 201117
Emadedin
et al., 201218
Haleem
et al., 201019
Kasemkij
wattana
et al., 201120
Lee et al.,
201223
Teo et al.,
201221
Wakitani
et al., 201122
1 Yes No No No No No No Yes
2. A) Yes No No No No No No No
B) Yes No No No No No No No
3. A) No No No No No No Yes Yes
B) Un No No No No No No No
4. A) Yes No No No No No No No
B) Yes No Un Un Un Un Un Un
5. A) Yes No No No No No No Yes
B) Yes No No No No No No No
6. Yes No No No No No No No
7. Yes No No No No No No Yes
8. Yes Yes Yes Yes Yes Yes Yes Yes
For the description of items 1e8 see Table II. Un: unable to determine.
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procedural related complication and was successfully treated with
oral antibiotics9. The onset of the pulmonary embolism was 2
weeks after the BMA before the initiation of any stem cell therapy
andwas documented as a possible procedural related complication.
The patient was successfully treated in hospital9. Two tumours
were detected in the period after the stem cell procedure in two
separate patients. One patient was diagnosed with a benign
schwannoma from T12-L2 and another patient was diagnosed with
prostate carcinoma. The stem cell implantations were in the hip
and knee joint respectively. Both tumours were not at the site of
injection and were reported by the authors as unrelated9.
AEs
All complications related to the harvesting procedure of stem
cells or to the administration procedure were self-limited or were
remedied with simple therapeutic therapies9,17.
Seven complications were reported as related to the stem cell-
product. All these patients reported increased pain and swelling.Table V
Procedure-related complications
First author, year of
publication
Number of
procedures
[subjects]
Mean follow-up period
 SD (range)
SAE/AE
Centeno et al., 20119 709, [>279]y 435days  261 days SAE
AE
Davatchi et al., 201117 4, [4] 14.2 months SAE
AE
Emadedin et al., 201218 6, [6] 1 year
Haleem et al., 201019 5, [5] 1 year
Kasemkijwattana
et al., 201120
2, [2] 30.5 months (30e31)
Lee et al., 201223 70, [70] 24.5 months
Teo et al., 201221 3, [3]* NA
Wakitani et al., 201122 45, [41] 75 months (5e137)
Our deﬁnitions: SAE included death, neoplasms, infections, pulmonary embolisms, anap
* These three patients are part of a larger group, of which 20 received ACI. Therefore
y Including three patients of three Case reports of Centeno et al., 2008 and 222 proced
exclusion of disc procedures and other site treatments.In four cases, drainage via arthrocentesis was required to resolve
swelling and pain and in one case, an injection of corticosteroids
was administered besides drainage. One stem cell treatment was
cancelled due to an insidious onset of knee swelling, 2 weeks after
procedure. This patient was eventually treated with a total knee
arthroplasty (Tables VeVII).
Discussion
The aim of this systematic review is to provide an overview of
AEs of the application of culture-expanded stem cells in joints. All
published studies with human cases were included to provide an
extensive overview of reported AEs. Of the 844 intra-articular im-
plantations with MSCs, four individuals were presented with a
serious complication. Two of the four serious complications were
probably related to the procedure: an infection at the BMA site and
a pulmonary embolism 2 weeks after BMA. Two tumours reported
were regarded unrelated9.
The eight included studies showed no safety issues regarding
the MSC-product. The only reported stem cell-product related AEsProcedure
location
Procedure complications reported
as probably/possibly related
Loc Sys
Crista iliaca Infection at bone marrow draw site: 1 X
Crista iliaca Pulmonary embolism 2 weeks after BMA: 1 X
Crista iliaca (2) Increased pain at site of BMA: 2 X
Crista iliaca (2) Dehydration after BMA: 2 X
Crista iliaca Recurrence of herpes zoster after BMA: 1 X
Ankle Urticaria after procedure: 1 X
Knee (8), hip (4),
facet (l)
Increased pain/swelling at implantation
site: 13
X
Knee Laboratory abnormalities: Transient
elevation of LFT: 1.
X
Hand Transient numbness and tingling in the
arm used for blood draw: 1
X
None
Knee Mild swelling: 1 X
None
None
None
None
None
None
hylactic shock and leukaemia. Loc: local AE, Sys: systemic AE, NA: Not available.
follow-up cannot be reduced.
ures of Centeno et al., 2010. The exact number of patients is not determinable after
Table VI
Stem cell-product related complications
First author, year of
publication
Number of
procedures
[subjects]
Mean follow-up period
 SD (range)
SAE/AE Procedure
location
Stem cell product
complications reported
as probably/possibly related
Loc Sys
Centeno et al., 20119 709, [>279]y 435 days  261 days SAE None
AE Knee (6),
Ankle (1)
Increased pain/swelling: 7 X
Davatchi et al., 201117 4, [4] 1 year None
Emadedin et al., 201218 6, [6] 1 year None
Haleem et al., 201019 5, [5] 14.2 months None
Kasemkijwattana et al., 201120 2, [2] 30.5 months (30-31) None
Lee et al., 201223 70, [70] 24.5 months None
Teo et al., 201221 3, [3]* NA None
Wakitani et al., 201122 45, [41] 75 months (5e137) None
Our deﬁnitions: SAE included death, neoplasms, infections, pulmonary embolisms, anaphylactic shock and leukaemia. Loc: local AE, Sys: systemic AE, NA: Not available.
* These three patients are part of a larger group, of which 20 received ACI. Therefore follow-up cannot be reduced.
y Including three patients of three Case reports of Centeno et al., 2008 and 222 procedures of Centeno et al., 2010. The exact number of patients is not determinable after
exclusion of disc procedures and other site treatments.
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is difﬁcult to attribute these stem cell-product related AE to one
cause. Prerequirements for stem cell therapy are suitable cell
counts and culture passages and applicable compositions of MSC
solutions or constructs for injection and implantation. Different cell
counts, passages and compositions of MSC solutions or constructs
are used in the included studies. These factors can all potentiallyTable VII
Reported unrelated AEs
First author, year
of publication
Number of
procedures
[subjects]
Mean follow-up
period  SD (range)
SAE/AE
Centeno et al., 20119 709, [>279]y 435days  261
days
SAE
AE
Davatchi et al., 201117 4, [4] 1 year
Emadedin et al., 201218 6, [6] 1 year
Haleem et al., 201019 5, [5] 14.2 months
Kasemkijwattana et al., 201120 2, [2] 30.5 months (30-31)
Lee et al., 201223 70, [70] 24.5 months
Teo et al., 201221 3, [3]* NA
Wakitani et al., 201122 45, [41] 75 months (5e137)
Our deﬁnitions: SAE included death, neoplasms, infections, pulmonary embolisms, anap
* These three patients are part of a larger group, of which 20 received ACI. Therefore
y Including three patients of three Case reports of Centeno et al., 2008 and 222 proced
exclusion of disc procedures and other site treatments.affect the occurrence of AE. For each individual AE information
regarding these factors would be of great interest. However, our
included studies did not provide this AE information speciﬁcally
per patient.
Other clinical studies using culture-expanded MSCs for other
applications also did not show any safety problems15,33,34. In
Duijvestein et al. administration of autologous MSCs in nineProcedure
location
AEs reported as unrelated
Knee (l), Hip (1) Tumour: 2
Hip TIA: 1
Hip MRSA infection: 1
Knee (7), Hip (ll),
Ankle (2), Hand (l),
Shoulder (l)
Increased pain and swelling, in most cases: most likely
progression of underlying disease: 22
Knee (4), Hip (5) Increased pain outside re-implant area: 9
Hip Cardiac problems: 1
Knee (l), Hip (3), Laboratory abnormalities: 5
Hand (l)
Knee, hip Low grade fever: 1
Knee Adrenal gland on unrelated lumbar MRI: 1
Hip Popping sensation in mouth with numbness
and drooling: 1
Hip Involuntary tremors in treated leg: 1
Knee Arm swelling after peripheral blood collection: 1
Knee Kidney stone pain: 1
Hip Sore throat and congestion: 1
Knee Tightness in hamstrings and gluteus: 1
Knee Polymyalgia rheumatica: 1
Knee Bronchitis: 1
Knee Excema and Barrack’s disease: 1
Hip Dermatomyositis: 1
Knee (2) Osteoporosis: 2
Hip Shingles after BMA: 1
None
None
None
None
None
None
None
hylactic shock and leukaemia. NA: Not available.
follow-up cannot be reduced.
ures of Centeno et al., 2010. The exact number of patients is not determinable after
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disease15. Likewise, Karamouzian et al. concluded that trans-
plantation of culture-expanded MSCs via lumbal puncture in 11
complete spinal cord injured patients at thoracic level is a safe
technique33.
To provide an impression of the number of AE in relation to
other intra-articular treatments, we have compared stem cell in-
jections with hyaluronic acid and high molecular hylan injections.
For this comparison we have used the data on stem cell injections
from the study of Centeno et al., because this is the only study with
an adequate method for AEs collection. In this study 23 (3.2%) AE
related to the intra-articular injection with stem cells or the stem
cell product were reported9. The systematic review and meta-
analysis of Reichenbach et al.with a total of 890 hyaluronic acid and
650 hylan treatments reported 42 (4.7%) local AEs in the hyaluronic
acid group and 50 (7.7%) in the high molecular hylan injection
group35. This would mean that intra-articular treatments with
culture-expanded stem cells have at least a comparable number of
AE with hyaluronic acid and hylan treatments.
The follow-up period differed greatly among the included
studies. Six studies reported a mean follow-up period between 12
and 31 months9,17e20,23. The group of Wakitani reported a follow-
up range from 2 to 11 years, with a mean follow-up of 6 years22.
One year of follow-up will probably not be sufﬁciently long enough
to detect all SAEs such as neoplasms. However, many animal
studies showed no evidence of neoplasms at stem cell re-
implantation sites36e39. Of two studies that did show sponta-
neous malignant transformation of human tissue-derived culture-
expanded MSCs, following extended culture and implantation in
mice, one was retracted40,41 and the other discussed42,43by the
authors in a later paper based on suspected cross-contamination
with human ﬁbrosarcoma or osteosarcoma cell lines.
All included studies used autologous bone marrow-derived
MSCs. Companies such as Mesoblast are developing off-the-shelf
adult stem cell products that are obtained from a single donor,
commercially expanded and frozen, and subsequently used in
allogeneic recipients. However, knowledge about the safety of the
use of allogeneic MSCs is limited. Of the studies included, seven
used fetal calf or bovine serum for cell culturing/expansion
(Table I)17e23. The use of animal-based serum during the expansion
of the stem cells could increase the risks of possible disease
transmission and reactions of the immune system44e47. To assure
maximal safety during the period of culture, contact of MSCs with
animal-derived supplementary products must be minimal. There-
fore the use of alternative methods of cell culturing such as autol-
ogous serum and platelet lysate increases. Each change or
difference in the culture procedure can inﬂuence cell population,
cell phenotype and consequently cell behaviour. Therefore this
review is only the beginning of exploring the safety of intra-
articular treatment with culture-expanded stem cells.
A limitation of our review is that most studies did not classify
the observed AEs. Well-described AE collections lacked in all
included studies except in the study of Centeno et al. 20119.
Furthermore, unpublished studies with detrimental results and
studies which did not mention AEs, may have caused publication
bias. In this review there were two studies with a total of 37 pa-
tients excluded because they did not give information on presence
or absence of AEs48,49.
We have extracted the data and subdivided the AEs into three
categories: local/systemic, SAE/AE, related/unrelated. Centeno et al.,
2011 reported two of the three categories9, the other studies did not
categorise the AEs. Clear classiﬁcation of AEs for orthopaedic ap-
plications of stem cells is warranted in future study reports.
Furthermore, it is not unlikely that uncommon side effects are
not reported yet or which may arise after a longer and accuratefollow-up. Future studies should include adequate methods
regarding the AEs collection using prospective checklists or patient
questionnaires/patient diaries for symptoms, (non)invasive tech-
niques for evaluation for structural changes such as enhanced MRI
or arthroscopy, and laboratory controls.
In conclusion, intra-articular cell-therapy with culture-
expandedMSCs appears to be safe based on 844 treatments in eight
studies. Based on the reported AEs and their classiﬁcation in this
systematic literature review we conclude that there are no
compelling arguments against proceedingwith intra-articular stem
cell application in human cases.
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